Blueprint Medicines Corp
BPMC
ISIN null / Valor 27670715
Blueprint Medicines Corp
UMushroom community rating:
About company
Blueprint Medicines Corp is a global biopharmaceutical company dedicated to developing targeted therapies for patients with serious diseases, particularly in the areas of oncology, hematology, and allergy/inflammation. The company has successfully brought two medicines to market and maintains a robust pipeline of investigational treatments aimed at addressing the underlying causes of various conditions. Leveraging its deep biological expertise and advanced drug design capabilities, Blueprint Medicines focuses on precision medicine approaches to create innovative solutions. Additionally, the company supports its development efforts with comprehensive clinical and commercial infrastructure, enhancing its ability to advance and commercialize novel therapies effectively.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (19.11.2025):
Blueprint Medicines Corp reported robust Q1 2025 financial and operating results, demonstrating strong revenue performance and strategic initiatives. The company achieved notable growth in AYVAKIT revenue, with continued investment in its pipeline and a disciplined approach to capital allocation, highlighting its solid financial foundation and promising outlook.
Revenue Growth
The company posted $149.4 million in AYVAKIT revenue during Q1 2025, marking a 61% year-over-year increase. This robust performance underscores Blueprint Medicines Corp’s effective market penetration in treating mast cell-driven diseases.
Guidance and Future Growth
Blueprint Medicines Corp raised its fiscal year 2025 AYVAKIT revenue guidance to $83.1 million (Ex-US) and is on track for $2 billion in global revenue by 2030, reflecting continued confidence in long-term market expansion.
Financial Strength
With approximately $900 million in cash on hand, the company maintained a disciplined capital allocation strategy, positioning itself well to navigate broader macroeconomic challenges while investing in growth opportunities.
Pipeline Progress
In addition to strong commercial results, Blueprint Medicines Corp advanced its clinical pipeline by initiating proof-of-concept studies for BLU-808 and progressing enrollment in the HARBOR trial of elenestinib for ISM, strengthening its future revenue prospects.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
8361 M
Market cap (USD)
Daily traded volume (Shares)
88.48 / 85.95
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
